BCL2 and B-cell chronic lymphocytic leukemia: To study the role of BCL2 in HSC activation and fibrosis, we used Venetoclax, a selective inhibitor approved by the Food and Drug Administration (FDA) for chronic lymphocytic leukemia patients with chromosome 17 p deletion [55].